Clinical Trials
23 trialsNCT06295809 2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT06870487 2026-05-08
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Phase 1 Terminated
NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT03886181 2025-12-08
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Terminated
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT04301011 2025-04-23
RAPTOR
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT04337931 2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
Phase 2 Terminated
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT04311710 2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1 Terminated
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03684785 2022-04-07
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
Phase 1/2 Terminated
NCT03497455 2021-12-29
Utility of Digital Dermoscopy in the Skin Cancer Clinic
Barco NV
Terminated
NCT02521870 2021-08-03
SYNERGY-001
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT01683188 2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4 Terminated
NCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT03391050 2019-07-31
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Aprea Therapeutics
Phase 1/2 Terminated
NCT02602067 2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1 Terminated
NCT01700114 2016-03-11
Post-Approval Study of MelaFind
MELA Sciences, Inc.
Terminated
NCT00689065 2013-11-01
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Phase 1 Terminated
NCT00865878 2011-10-21
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
DUSA Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00735332 2010-08-05
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
Thallion Pharmaceuticals
Phase 2 Terminated